Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications.
HematologySep 4, 2026 (epub)
Clinical ResearchHematology
Pankit Vachhani, Jennifer Repp, J E Hamer-Maansson et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of the phase 3b JUMP trial examined the effects of adding anemia-supporting medications to ruxolitinib in 101 patients with myelofibrosis and anemia. The study found that 37% of patients achieved a spleen length response at Week 24, indicating comparable outcomes to the overall JUMP population.
Key findings
- 37% of patients achieved a spleen length response at Week 24.
- 26% of patients achieved a symptom response, similar to the comparator group.
- Hemoglobin levels increased after Week 4 following an initial decrease.
Why it matters
Understanding the impact of anemia-supporting medications in conjunction with ruxolitinib can help clinicians optimize treatment strategies for patients with myelofibrosis and anemia, potentially improving patient outcomes.